Bispecific Antibodies Market By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597), By Application (BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, and Others), By End-User (Hospitals, Clinics and Research Centers) and By Region - Market Trends, Analysis, and Forecast till 2030.

The market for bispecific antibodies was valued at US$484.9 million in 2019 and is projected to grow at a compound annual growth rate (CAGR) of 6.6% to reach US$915.4 million by 2029.

Artificial proteins called bispecific antibodies are created by combining two or more antigen-recognizing components into a single construct. Bispecific antibodies can bind to two or more targets simultaneously. The structure of the antibodies includes minimally sized biospecific antibodies, bispecific antibodies with unique heterodimerization domains, chemical heteroconjugates, and quadromas. Delivering payloads to the intended location and dual targeting of disease mediators are two benefits. The FDA approved Catumaxomab and blinatumomab, two bispecific antibody products. Several important researchers are working on symmetric bispecific antibodies. Some asymmetric bispecific antibodies targeted by major players like Eli Lilly and Company and Genmab A/S are BEAT, nobody, and crosstab.